NORGESIC FORTE by Bausch + Lomb is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. First approved in 1964.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
NORGESIC FORTE is an oral combination tablet containing orphenadrine citrate, aspirin, and caffeine approved in 1964 for musculoskeletal pain and spasm. It is a centrally-acting muscle relaxant that blocks facilitatory functions in the brain stem reticular formation, combined with analgesic and mild stimulant properties. The product treats acute muscle pain and associated functional limitations in patients who do not respond to aspirin alone.
Declining Part D spending and minimal claim volume indicate a shrinking commercial footprint with likely reduced team capacity and investment.
CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job count reflects minimal hiring activity and compressed team structure typical of mature, declining products. Career opportunities are limited to account management and legacy brand support roles with constrained growth potential.
Worked on NORGESIC FORTE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo